aTyr Pharma, Inc.’s (ATYR) Failed Drug Trial Spurs Securities Lawsuit — Hagens Berman
A federal class-action lawsuit has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) following a devastating 83% drop in the biotech company's stock price after its lead drug candidate failed to meet its primary endpoint in a critical Phase 3 trial. https://mma.prnewswire.com/media/2590203/Hagens_Berman_Sobol_Shapiro_LLP_Logo.jpg Prominent shareholders rights firm Hagens Berman has been investigating the alleged claims. Blog:www.hbsslaw.com/blog […]